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safety. When comparing the direct anticoagulant dabigatran 
with warfarin no difference in stroke prevention at higher TTR 
was shown.(3) TTR greater than 70% conferred better survival 
for patients with moderate or high-risk patients.(4) In patients 
with AF, the quality of anticoagulation is stratified according to 
the percentage TTR where less than 50% is considered bad 
quality, more than 60% being satisfactory and more than 70% 
conferring optimal anticoagulation. The report from a post-hoc 
analysis of the Atrial Fibrillation Clopidogrel Trial with Irbesartan 






Warfarin is a vitamin K antagonist and is widely prescribed as an 
oral anticoagulant for treating and preventing thrombosis and 
embolism in atrial fibrillation (AF) and in prosthetic heart valves 
(PHV).(1) Due to its complex pharmacokinetics, pharma-
codynamics and inter-individual variability, there is usually no 
standard dose and therefore international normalised ratio 
(INR) testing is required to monitor its efficacy and reduce the 
risk of bleeding complications. The quality of this anticoagulation 
is less often measured and the time in the therapeutic range 
(TTR) is an important, validated, and acceptable measure of 
this. The three most common methods of evaluating TTR are 
the fraction of INRs in range or the direct method (number of 
INRs in range divided by the number of INRs tested as a 
percentage); the Rosendaal linear interpolation method which 
assumes a linear relationship between 2 INR values and com-
putes the INR for any specific day; and the cross-section-of-
the-files method which takes each patient whose INR is in 
range at one point in time divided by the total number of INRs 
performed on all patients at that point in time.(2)
The TTR is a measurement not only of the efficacy of anti-
coagulation with warfarin but also as a measure to ensure its 
* Division of Internal Medicine, School of Clinical Medicine, College 
of Health Sciences, University of KwaZulu-Natal, Durban, 
KwaZulu-Natal, South Africa
# Clinical unit, Mahatma Gandhi Memorial Hospital, Durban, 
KwaZulu-Natal, South Africa
Address for correspondence: 
Dr D. Sadhabiriss








D. Sadhabiriss* and S.L. Brown*,# ABSTRACT
Background: Two common indications for oral anti-
coagulants are patients with non-valvular atrial fi bril-
lation (AF) or prosthetic heart valves (PHV). The degree 
of anticoagulation is monitored by evaluating the inter-
national normalised ratio (INR); however, the quality of 
anticoagulation, determined by the time in therapeutic 
range (TTR), is less often evaluated. TTR has signifi cant 
clinical implications in patient outcomes. 
Objectives: We sought to identify the indications for 
anticoagulation and determine its quality via the TTR 
at a single centre, community-based and district level 
hospital in the setting of usual care. We documented 
the prevalence of thrombo-embolic and haemorrhagic 
adverse events and we also collected data on factors 
that may contribute to a poor TTR or increased risk of 
adverse events. 
Methods: We conducted a retrospective, descriptive and 
observational study with chart audits evaluating the 
anticoagulation indication and control for the preceding 
1 year for each patient. Descriptive statistics included 
mean and standard deviation for quantitative data and 
frequencies for categorical data. Chi-square tests were 
used to analyse comparisons of categorical data and 
the student’s t-test for continuous variables. Two-tailed 
p-values less than 0.05 were considered signifi cant.
Results: TTR was poor for patients with AF and PHV 
(44.5% and 13.7% respectively). We identifi ed older age, 
less frequent testing and high target ranges as signifi cant 
factors associated with poorer outcomes. We demon-
strated a high prevalence of adverse events (25.4%).
Conclusion: Patients in this setting demonstrated poor 
quality of anticoagulation and had a high prevalence of 













outpatient department at Mahatma Gandhi Memorial Hospital 
in KwaZulu-Natal, South Africa. This comprised a setting of 
usual care and not a specialised anticoagulation clinic. We 
included all patients using warfarin for AF or PHV for at least 
one year. We excluded patients who had interrupted warfarin 
therapy for longer than 2 months and inpatient INR testing. 
The target INR value for patients with PHV was determined 
using established recommendations(1) which consider valve 
thrombogenicity and patient risk factors in determining the 
target INR. To create a target INR range, we accepted these 
targets as the minimum acceptable INR value and allocated a 
0.5 higher limit to create a range. The target INR range for 
patients with AF was consistent at 2.0 - 3.0. These recom-
mendations are consistent with the laboratory reference at the 
study site to ensure consistency between the treating clinician 
and the study methods. The TTR was determined by the direct 
method and the Rosendaal method. Time out of range (time 
below range, above range and with an INR greater than 4.00) 
was determined using only the direct method. Documented 
adverse events at any time for a particular patient were included 
unless sustained before commencing warfarin therapy. Adverse 
events were categorised as stroke and haemorrhage or over-
warfarinisation (determined as needing antidote treatment or 
inpatient care). 
Statistical analysis
Data were analysed by the IBM Statistical Package for the Social 
Sciences for WindowsR, version 23 (IBM Corp., Armonk, N.Y., 
USA) software programme. Descriptive statistics included 
mean and standard deviation for quantitative data and fre-
quencies for categorical data. The student’s t-test and the chi-
square test were used for comparison of data. The Pearson 
correlation test was used to compare the Direct and the 
Rosendaal methods. Any 2-tailed p-value less than 0.05 were 
considered significant.
Ethical considerations
This study commenced following full ethical approval ob-
tained from the Biomedical Research Ethics Committee, 
University of KwaZulu-Natal (ref.no.BE320/15) and permis-
sions from the KwaZulu-Natal Department of Health (ref.
no.KZ_2016RP26_295). The study was conducted in accor-
dance with the National Institutes of Health Office of Extra-
mural Research course (Certification No. 1768624).
the TTR was below 58% - 65%, the benefit of warfarin therapy 
over aspirin was lost.(5)
Valve thrombosis is most often encountered in patients with 
mechanical valves and inadequate antithrombotic therapy.(6) 
A correlation between treatment quality with warfarin as 
measured by TTR and serious complications has been shown. It 
is recommended that best benefit in patients with PHV is 
achieved when the TTR is at least 83% but a TTR of at least 
70% is likely to be sufficient to prevent valve thrombosis.(7)
Further to the efficacy of anticoagulation, improved TTR confers 
reduced risk of bleeding and mortality and is therefore con-
sidered as a measure to ensure safety in anticoagulation. In the 
Stroke Prevention using an Oral Direct Thrombin Inhibitor in 
Atrial Fibrillation (SPORTIF III) trial, patients with a TTR of less 
than 60% had significantly higher incidence of major haemor-
rhage and mortality than patients with TTR above 75%.(8) The 
study by Wan, et al., evaluated anticoagulation control and 
prediction of adverse events in patients with AF by a systemic 
review of 47 studies. They found that TTR negatively correlated 
with major haemorrhage and thrombo-embolic rates. This 
effect was significant in retrospective but not in randomised 
controlled trials. For retrospective studies, a 6.9% improve-
ment in the TTR significantly reduced major haemorrhage by 1 
event per 100 patient-years of treatment. Furthermore, they 
concluded that a 12% increase in TTR can reduce the thrombo-
embolic rate by 1 event per 100 patient-years.(9) Data from 
the Rivaroxaban once daily oral direct factor XA inhibition 
compared with vitamin K antagonism for prevention of stroke 
and embolism trial in atrial fibrillation (ROCKET-AF) trial 
evaluated the relationship between TTR and the comparative 
treatment effects of rivaroxaban and warfarin and found that 
patients in the highest quartile of TTR had a lower event rate 
per 100 person-years than patients in the lowest quartile of 
TTR (1.3 vs. 2.0) when analysing stroke or systemic thrombo-
embolism.(10)
It is therefore accepted and emphasised that the TTR matters 
and has far reaching implications in both assessing the quality 
of anticoagulation, determining efficient anticoagulation, and 
reducing the incidence of mortality and major adverse events.
MATERIALS AND METHODS
Study sample 
We conducted a retrospective, descriptive and observational 
study with chart audits of patients attending the adult medical 
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RESULTS
Description of the sample population
We evaluated 263 patients who were on warfarin. The most 
common indication was for stroke prevention in non-valvular 
AF (39.5%) followed by PHV (35.8%). Venous thrombosis or 
embolism (12.2%), arterial or left ventricle thrombus (4.9%), 
valvular AF (3.8%) and heart failure with reduced ejection frac-
tion (0.4%) comprised the remaining indications. Charts could 
not be located for 9 (3.4%) patients. Hereinafter, we excluded 
86 cases (65 patients on warfarin for reasons other than non-
valvular AF and PHV and a further 21 patients who had less 
than 1 year of warfarin use). This resulted in a sample population 
of 96 patients with AF and 81 patients with PHV (Figure 1). 
Most patients were female (n=122, 68.9%). The mean age of 
patients with AF was 64.68 ± 11.3 years and 41.83 ± 15.7 years 
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for patients with PHV. Patients with AF were categorised in line 
with the CHA2DS2-Vasc scoring system; 34 (35.4%) patients 
were 65 years old to less than 75 years old and 17 (17.7%) 
patients were 75 years or older.(11) The AF cohort was evalu-
ated for 39 937 days with a mean of 416 ± 111.8 days per 
patient and patients with PHV for 39 038 days with a mean of 
481.9 ± 192.4 days per patient. The mean number of days 
between INR tests for the entire cohort was 33.3 ±12.0 days; 
31.05 ± 6.8 days for the AF cohort and 35 ± 15.8 days for 
those with PHV. A total of 2 382 INR values were analysed; 
1 285 for patients with AF cohort and 1 097 in those with 
PHV. (Table 1).
Time in therapeutic range
Patients with AF had a significantly higher percentage of TTR 
than patients with PHV when tested by the direct and the 
FIGURE 1: Selection of patients for the study analyses. 
VTE = Venous thromboembolism, DVT = Deep vein thrombosis, PE = Pulmonary embolus, LV = Left ventricle, AF = Atrial fi brillation, 
HFrEF = Heart failure with reduced ejection fraction, NVAF = Non-valvular atrial fi brillation.
65 cases excluded warfarin for other indications
     32 patients - VTE/DVT/PE
     13 patients - Arterial/LV Thrombus
     10 patients - Valvular AF
       1 patient - HFrEF
       9 patients - Charts not located
21 cases excluded warfarin use less than 1 year
     38 patients - NVAF subgroup
    13 patients - Valve prosthesis
263 patients on warfarin
For any indication
198 patients on warfarin
For NVAF or prosthetic heart valves
177 patients on warfarin
96 patients on warfarin for NVAF













Rosendaal methods (41.9% ± 19.6 vs. 13.8% ± 12.7; p<0.001 
and 44.5% ± 18.5 vs. 13.7% ± 11.9; p<0.001 respectively).
Patients with AF spent significantly less time below range than 
the patients with PHV (29.19% ± 19.9 compared to 67.69% ± 
20.0; p<0.001) and significantly more time above range than 
the patients in the valve prosthesis cohort (28.38% ± 17.2 
compared to 18.61% ± 13.9; p<0.001). The mean percentage 
time with an INR value of greater than 4.0 was significantly 
lower in the AF cohort (9.11% ± 11.04) than the valve pros-
thesis cohort (13.34% ± 10.9); p=0.012 (Table II). A positive 
correlation between the results of the direct and the Rosendaal 
methods using a Pearson correlation test (r=.823, p<0.001) 
was demonstrated.
A total of ten (10.4%) patients in the AF cohort had INR values 
in the therapeutic range for more than 70% of the time and 
therefore considered to have good anticoagulation; 73 (76.1%) 
patients were in therapeutic range for less than 60% of the 
time and had suboptimal anticoagulation and at increased risk 
for thrombotic events and 62 (84.9% of this subset or 64.6% 
of all patients with AF) patients demonstrated a bad quality of 
anticoagulation (Figure 2).
The mean TTR in 81 patients with PHV was less than 14%. 
None of the patients with PHV in our study demonstrated a 
satisfactory quality of anticoagulation and all patients did not 
achieve the minimum desired level of 70% TTR.
Factors associated with time in range and time 
out of range
Gender
There was no difference in TTR between males and females 
when using either the direct or Rosendaal method (p=0.165 
and p=0.640, respectively). Males with AF spent significantly 
more time with sub therapeutic INR values compared to 
females (35.5% vs. 25.5%, p=0.044). Overall, the mean TTR 
in patients with PHV was low and there was no gender dif-
ference demonstrated (p=0.684 and p=0.729 for the direct 
and Rosendaal methods, respectively).
Age
In patients with AF, the mean TTR was similar for patients less 
than 65 years old, 65 years to less than 75 years old and patients 




Total days studied (mean per patient)
Total INRs sampled (mean per patient)
Mean days between INR tests (SD)
  Less than 28 days apart, n (%)
  28 - 32 days apart, n (%)
  More than 32 days apart, n (%)   
122 (68.9)










  Less than 65 years old, n (%)
  65 to less than 75 years old, n (%)
  75 years or older, n (%)
Total days studied (mean per patient)
Total INRs sampled (mean per patient)
Mean days between INR tests (SD)
  Less than 28 days apart, n (%)
  28 - 32 days apart, n (%)
  More than 32 days apart, n (%)
63 (65.6)










Valve prosthesis cohort (n=81)
Female, n (%)
Mean age (IQR)
  Less than 20 years old, n (%)
  20 - 29 years old, n (%)
  30 - 39 years old, n (%)
  40 - 49 years old, n (%)
  50 - 59 years old, n (%)
  60 years or older, n (%)
Total Days studied (mean per patient) 
Total INRs sampled (mean per patient)
Mean days between tests (SD)
  Less than 28 days apart, n (%)
  28 - 32 days apart, n (%)
  More than 32 days apart, n (%)
59 (72.8)













AIQR = Inter-quartile range, INR = international normalisation ratio, 
AF = Atrial fibrillation.
TABLE 1I: Distribution of mean percentage time in range 







Mean age in years 64.7 41.8
Female, n (%) 63 (65.6) 59 (72.8)
Time below range (%) 29.2* 67.7
Time above range (%) 28.4* 18.6
Time INR >4.00 (%) 9.1** 13.3
TTR-Direct method (%) 41.9* 13.8
TTR-Rosendaal method (%) 44.5* 13.7
*p<.001 when compared to valve prosthesis subgroup using independent samples t-test.
**p<.05 when compared to valve prosthesis subgroup using independent samples t-test.
AF = Atrial fibrillation, INR = International normalised ratio, 
TTR = Time in therapeutic range.
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at least 75 years old (41.7%, 40.7% and 44.7%, respectively, 
p-=0.794). There was no age association and TTR in patients 
with PHV.
INR testing frequency
In patients with AF, there was no significant association of TTR 
and time out of range when the INR testing intervals were 
considered (p=0.984, p=0.613, p=0.792, p=0.911 for TTR, 
time below range, above range and time above INR of 4.00 
respectively). The INR testing interval was significantly asso-
ciated with TTR and time out of range in patients with PHV. 
Analysis by the Rosendaal method, demonstrated patients 
who had INR tests between 28 and 32 days apart had higher 
TTR than those who had tests more than 32 days apart (17.4% 
vs. 10.4% respectively, p=0.023). Further, patients who had 
tests less than 28 days apart had significantly less time below 
range than those tested more than 32 days apart (68.7% and 
74.4% respectively, p=0.030). The time above range was also 
significantly influenced by INR testing interval in patients with 
PHV; patients tested more than 32 days apart spent significantly 
less time above range than those tested 28 - 32 days apart 
(13.6% and 22.4%, p=0.030) as well as when compared to 
patients tested less than 28 days apart for time with an INR 
value exceeding 4.00 (9.3% and 18.8%, p=0.016).
INR Target range
All patients with AF constituted the subgroup of patients with a 
target INR of 2.0 - 3.0. Most patients with PHV had a target INR 
range of 3.5 - 4.0. Fourteen (17.3%) and 21 (25.9%) patients 
had target ranges of 2.5 - 3.0 and 3.0 - 3.5, respectively. Patients 
with the lowest target INR range had significantly superior TTR 
than those with target ranges of 2.5 - 3.0, 3.0 - 3.5 and 3.5 - 4.0 
(44.5% vs. 30.0%, 12.1% and 9.4% respectively, p<0.001). Con-
sistent with this finding, this subgroup of patients had signifi-
cantly less time below range (29.2% vs. 42.6%, 70.1% and 74.2% 
respectively, p<0.001). However, patients with a target INR of 
2.0 - 3.0 demonstrated significantly more time above range 
than those with highest 2 tiers of target ranges (28.4% vs. 17.9% 
and 15.5% respectively, p<0.05). There was no difference when 
evaluating time with an INR above 4.00. Similarly, patients with 
PHV with the lowest target range i.e., 2.5 - 3.0 demonstrated 
superior TTR than those with higher targets as well as less 
time below range and more time above range (44.5% vs. 12.1% 
and 9.4%, p<0.05; 29.2% vs. 70.1% and 74.2%, p<0.05; 29.9% 
vs. 15.5%, p<0.05 respectively) (Table III). 
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Valve prosthesis n=81AF Cohort n=96
FIGURE 2: Distribution of patients in the AF cohort (n=96) and valve prosthesis cohort (n=81) according to percentage 
TTR according to the Direct method and the Rosendaal method. Percentages reflect that of the specific cohort. 
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  Less than 65 years old
  65 to less than 75 years old





















Days between INR tests
  Less than 28 days apart
  28 - 32 days apart









































  Less than 20 years old
  20 - 29 years old
  30 - 39 years old
  40 - 49 years old
  50 - 59 years old




































Days between INR tests
  Less than 28 days apart
  28 - 32 days apart






















  Target INR : 2.0 - 3.0 - n=96
  Target INR : 2.5 - 3.0 - n=14
  Target INR: 3.0 - 3.5 - n=21


























*Post hoc analysis Tukey HSD showed differences only between patients who were monitored less than 28 days apart and those monitored more than 32 days apart.
**Post hoc analysis Tukey HSD revealed a significant difference only between the group being monitored from 28 - 32 days apart and those patients being monitored more than 
32 days apart.  §p<.05when compared to target groups 2.5 - 3.0 by Tukey HSD post hoc analysis.  †p<.05 when compared to target groups 3.0 - 3.5 and 3.5 - 4.0 by Tukey HSD 
post hoc analysis.  ‡p<.05 when compared to target group 3.5 - 4.0 by Tukey HSD post hoc analysis.
INR = international normalised ratio, AF = Atrial fibrillation.
TABLE 1II: Factors associated with time in range and time out of range.
Adverse events
Thirty-one (17.5%) patients had at least 1 adverse event, 10 
(5.6%) of whom, sustained multiple events resulting in a total of 
45 documented adverse events (25.4% point prevalence). 
Stroke accounted for 21 of the events (46.7%) and haemor-
rhage or admission for over-anticoagulation the remaining 24 
(53.3%) events. There were no documented cases of an 
obstructed prosthetic valve. Patients with AF accounted for 28 
(62.2%) of the 45 adverse events, 18 (64.3%) of which were 
strokes. There were three strokes and 14 (82.4% of adverse 
34
events in PHV patients) haemorrhagic or toxic events in 
patients with PHV.
There was no gender association in patients who sustained an 
adverse event or between the types of event. In patients with 
PHV, the mean age of patients who did not sustain an adverse 
event was significantly lower than patients who had at least 1 
event (39.8 vs. 53.6 years, p=0.004). In patients with AF, the 
mean age showed no significant association with sustaining an 
adverse event, however, in those who did have an adverse 
event the mean age was significantly higher in patients who had 
bleeding or over-anticoagulation compared to those with 
stroke (74.4 years compared to 63.7 years respectively, 
p<0.05). The mean number of days between tests did not yield 
statistically significant differences when evaluating adverse 
events for either cohort.
Overall, the mean TTR was higher in patients with multiple 
events as compared to patients with only a single event (49.2% 
vs. 33.0%, p=0.012) however still with an undesirable TTR. 
There was no association in sustaining an adverse event with 
TTR. In the AF cohort, patients with a stroke spent significantly 
less time below range than those with haemorrhage or toxicity, 
otherwise there was no demonstrated difference for asso-
ciations with time out of range and adverse events. In patients 
with PHV, the target INR had no statistically significant asso-
ciations on adverse events (Table IV).















Mean days between tests
Mean time below range
Mean time above range
Mean time with INR >4.00
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Mean days between tests
Mean time below range
Mean time above range
Mean time with INR >4.00
Mean TTR
Target INR: 2.5 - 3.0
Target INR: 3.0 - 3.5
























































*- p<.05 when compared to patients with haemorrhage or toxicity.  **-p =.004 when compared to patients who sustained at least one adverse event.  †p=0.012 when compared to 
patients with only one event.
AF = Atrial fibrillation, TTR = Time in therapeutic range, INR = International normalised ratio.














The Global Burden of Disease study reported a male pre-
dominance of AF.(12) In contrast, females in our study constituted 
almost twice as many as males (65.6% vs. 34.4) and this finding 
was comparable to 2 South African studies evaluating patients 
on warfarin.(13,14) In the larger ROCKET-AF trial only 124 (2%) 
of the 6 983 patients were from South Africa;(10) 98 patients of 
the 6 706 patients represented South Africa in the ACTIVE-W 
study(5) and therefore the South African context may be less 
understood. In the South African context, women visit health 
centres more often and this coupled with the higher employ-
ment percentage of men over women may explain why women 
are higher represented in these studies. Nonetheless, the 
clinical implications of a female predominance in patients with 
AF confers the increased stroke risk consistent with CHA2DS2-
Vasc risk scoring. The mean age of patients with PHV is lower 
than those studied internationally and this is likely explained 
by the high prevalence of rheumatic heart disease as compared 
to high income regions which report a higher prevalence of 
degenerative valve lesions.(15)
The direct and the Rosendaal methods correlated well; this is 
consistent with reports of Caldeira, et al. in a study of 377 
patients and the meta-analysis by Wan, et al. where a good 
correlation between the two methods was demonstrated. (9,16) 
Patients with AF had a significantly higher TTR than those with 
PHV AuriculA, a Swedish study, evaluated INRs from 18 391 
patients in 67 different centres which reported patients with 
AF had a mean TTR of 76.5% and those with mechanical valves 
a TTR of 79.9%.(17) These findings contrast to those in our 
study although some study design differences exist; the parti-
cipants from AuriculA were not exclusively managed out of 
specialised anticoagulation clinics and that study utilised only a 
low target INR range of 2 - 3. Furthermore, AF represented 
most of the patients (64%) and heart valve dysfunction 
accounted for 13% whereas our study had almost equal repre-
sentation and a higher female representation. 
Only 10.4% of patients with AF had a TTR better than 70%. 
The ACTIVE-W,(5) ROCKET-AF,(10) ARISTOTLE(18) and RE-LY(19) 
were randomised controlled trials (RCT) which reported a 
mean TTR superior to that in our patients, however, the South 
African patients in these studies demonstrated less impressive 
TTR and is closer in line to our findings. In a South African study 
conducted at an anticoagulation clinic the mean TTR was 
48.5%.(14) Other studies which demonstrated superior mean 
TTR (69.7%) included the STABLE trial, which evaluated self-
monitoring.(20) However, our study evaluated patients in a usual 
care setting, not as part of a specialised anticoagulation clinic 
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and represents a real-life analysis and not part of an RCT, all of 
which may be significant factors contributing to poorer TTR. 
Bloomfields RCT demonstrated superior TTR in patients 
attending specialised anticoagulation clinics as compared to 
usual care.(21) Overall, the TTR is poorer in African countries 
compared to the European and Western Regions. This dif-
ference is likely contributed by the burden of communicable 
diseases and over-extended health care budgets and challenging 
socioeconomic conditions (Figure 3).
Patients with PHV demonstrated especially poor results with a 
mean TTR of less than 14% and all patients were categorised 
with suboptimal anticoagulation. Patients in this category were 
on average younger, had higher target INR values and had a 
more female representation, all of which are validated factors 
associated with poor quality of anticoagulation. 
Studies that evaluated factors impacting on TTR included 
Apostolakis, et al., which evaluated 4 060 patients with AF from 
the AFFIRM trial and reported female gender and a younger 
age to be associated with poor anticoagulation.(22) Dlott, et al., 
identified 138 319 individuals with AF and found females had 
lower TTR than males and reported a significantly better mean 
TTR in patients aged 75 years or older than those who were 45 
years or younger. They also found INR testing frequency was 
positively associated with TTR among patients with fewer than 
14 INR tests per year, but inversely associated with TTR among 
those with more frequent testing.(23) Rose, et al., in their US 
study, enrolled 3 396 patients from 101 community-based 
practices in 38 states and found a trend of poorer anticoagula-
tion quality in females but similar mean ages for patients with 
variable TTR and reported longer INR monitoring intervals to 
be associated with improved INR control. Further, they noted 
patients in the low target group had a lower mean percentage 
TTR than those with normal INR target range.(24) The STABLE 
study evaluated 29 457 patients who performed home moni-
toring and reported higher TTR in patients aged 65 to less than 
75 years old compared to patients between 46 - 64 years as 
well as in patients with more frequent INR testing.(20) Overall, 
patients in our study population had neither statistically signi-
ficant gender nor age association to TTR and time out of 
range. These findings are neither in line with the findings of 
Apostolakis, et al., Dlott, et al., Rose, et al. nor to the reports of 
the STABLE study. This may be due to the female representa-
tion in our study contrasting with the global reported pre-
valence; however, this finding is likely a result of the overall 
poor TTR across all age groups in our population. 
Patients with PHV demonstrated a superior TTR if monitored 
more frequently, which is in line with the findings from The 
Home INR Study (THINRS)(25) and the STABLE study. How-
ever, this was not consistent in patients with AF. Patients at 
our location are prescribed warfarin for a maximum of 28 days 
before prescription-renewal and it is likely that there were 
periods with no anticoagulation, and this is probably the reason 
for low INR values in patients tested less frequently. It is prob-
able that patients identified as being poorly anticoagulated or 
at high risk for adverse events may have been monitored 
more frequently.
Patients with the lowest target range had a superior TTR than 
patients with higher targets. This is contrary to the findings 
from the study by Rose, et al., where patients in the low target 
group had a lower mean percentage TTR than those with 
normal INR target range. However, the study by Rose, et al., 
was conducted on patients with AF and not with prosthetic 
valves and the target INR ranges were lower than for the 
patients with valve prostheses in this study. Our findings suggest 
that patients with low target ranges are easier to achieve 
effective anticoagulation but are also at risk for over-anti-
coagulation and therefore bleeding. 
Patients with AF sustained most of the adverse events, with the 
majority being stroke. Patients with PHV in our study had 14 
bleeding events and 3 stroke events. In the AuriculA trial, the 
frequency of bleeding events was 2.03% and 1.36% for throm-
bosis for the whole study population. The AF subgroup in that 
study demonstrated 2.13% cases of bleeding and 1.16% of the 
total AF subgroup accounted for thrombotic events. The sub-
group with heart valve dysfunction demonstrated 2.01% of 
bleeding and 2.35% of thrombosis. Connolly, et al., evaluated 
a regional influence using data from the ACTIVE-W trial.(5) 
Sonuga, et al., studied 136 patients attending an anticoagulation 
clinic in Cape Town, South Africa, of which 14% had bleeding 
events and 2.2% had thrombotic events.(14) While the high pre-
valence of adverse events in our study is closer to other South 
African samples, there are some differences between the 
studies. The participants in AuriculA demonstrated a much 
higher TTR (mean of 74.9%) than our patients. The AF cohort 
in AuriculA was not exclusively comprised of non-valvular AF 
and the patients in their valve disease subgroup included par-
ticipants not limited to mechanical prosthetic valves. The 
ACTIVE-W included myocardial infarction and death in their 













Interestingly, despite most of the patients with PHV having high 
percentage time below range, there were no documented 
events of valve thrombosis. The most likely reason is that valve 
thrombosis is rare and patients most susceptible to this event 
are those within the first 6 months of implantation. In our 
study, we evaluated patients on warfarin for at least 1 year and 
therefore the findings may not be inclusive of such patients. 
Furthermore, given the devastating effect of valve thrombosis 
and high risk of mortality, we may not have included these 
patients as we enrolled participants based on their attendance. 
STUDY LIMITATIONS 
The main limitation of this study was that it was retrospective 
and single centre based and may not be entirely representative 
for a region. It is, however, to the best of our knowledge the 
first study evaluating the quality of anticoagulation in a com-
munity-based and usual care setting for both AF and PHV in 
KwaZulu-Natal. Only outpatient folders were analysed and 
therefore INR values registered in inpatient files or at other 
facilities were not included as these would not constitute usual 
care. The patient population was derived from record keeping 
of INR sampling and therefore only live cases were analysed. As 
a result, we were unable to evaluate for associated mortality 
which remains the most important clinically relevant outcome. 
Nonetheless, we believe this method of sample recruitment 
remains the best to achieve the most real-life representation of 
anticoagulated patients in community practice.
Adverse events were reliant on the documentation of such by 
the attending clinician and this may have resulted in under-
representation of events. The most important limitations in 
evaluating events however, was the lack of documented neuro-
imaging findings and we were therefore unable to establish any 
stroke as ischaemic or haemorrhagic and the study design 
precluded us from accurately evaluating for haemorrhage as 
defined by the International Society of Thrombosis and 
Haemostasis guidelines(26) and this may have over-reported the 
number of major bleeding events. The data did not include 
some factors that are known to affect TTR like patient educa-
tion on warfarin use, patient compliance, concomitant drug use, 
socioeconomic conditions, ethnicity, tobacco use, alcohol use, 
warfarin resistance and lastly, although age was used as factor 
conferring high risk in AF, a complete CHA2DS2-Vasc assess-
ment was not performed.
CONCLUSIONS 
Non-valvular AF and PHV accounted for most cases requiring 
warfarin therapy. There is a poor quality of anticoagulation in 
AF and patients with PHV demonstrated especially poorer 
results. The study demonstrates a major gap in quality of anti-
coagulation compared to developed regions and confirms that 
most patients are not achieving the recommended minimum 
TTR of 60%. The fraction of INRs is a reasonable method for 
evaluating TTR and correlates well with the Rosendaal method. 
The lack of gender or age association with TTR suggest that in 
our region, both males and females, regardless of age have 
equally high risk for poor anticoagulation and therefore adverse 
events. A variable follow-up period based on recent INR results 
should replace fixed testing periods. Patients with the highest 
target ranges have the highest risk of inadequate anticoagula-
tion and may need closer monitoring. Further research is 
required to determine the factors contributing to poor anti-
coagulation in this population. Some considerations to improve 
the quality of anticoagulation include using a dedicated and 
specialised anticoagulation clinic, the use of point-of-care 
devices, adjustment of visit frequencies and perhaps the use of 
direct acting anticoagulants.
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